Anacor Pharmaceuticals Inc (ANAC) was Reiterated by Wedbush to “Outperform” while Lowering the Price Target of the company shares to $ 148 from a previous price target of $152 . Wedbush advised their investors in a research report released on May 3, 2016.
Many Wall Street Analysts have commented on Anacor Pharmaceuticals Inc. Mizuho Initiated Anacor Pharmaceuticals Inc on Mar 11, 2016 to “Buy”, Price Target of the shares are set at $103.
On the company’s financial health, Anacor Pharmaceuticals Inc reported $-0.43 EPS for the quarter, missing the analyst consensus estimate by $ -0.12 based on the information available during the earnings call on Feb 29, 2016. Analyst had a consensus of $-0.31. The company had revenue of $21.20 million for the quarter, compared to analysts expectations of $27.93 million. The company’s revenue was up 120.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.24 EPS.
Anacor Pharmaceuticals Inc opened for trading at $63.37 and hit $66.3499 on the upside on Monday, eventually ending the session at $66.08, with a gain of 5.32% or 3.34 points. The heightened volatility saw the trading volume jump to 7,01,959 shares. Company has a market cap of $2,964 M.
In a different news, on Apr 29, 2016, Ryan T Sullivan (EVP and General Counsel) sold 3,125 shares at $66.33 per share price. According to the SEC, on Apr 11, 2016, Anders D Hove (director) sold 229,301 shares at $72.29 per share price. On Mar 23, 2016, Paul L Berns (President and CEO) sold 37,500 shares at $60.17 per share price, according to the Form-4 filing with the securities and exchange commission.
Anacor Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on discovering developing and commercializing small-molecule therapeutics derived from its boron chemistry platform. The Company’s lead product candidate AN2728 is an investigational non-steroidal topical PDE-4 inhibitor in development for the potential treatment of mild-to-moderate atopic dermatitis and psoriasis. The Company’s product KERYDIN (tavaborole) topical solution is an oxaborole antifungal. The Company also has a pipeline of other internally discovered topical and systemic boron-based compounds in early stages of research and development which include AN3365. The Company’s compound AN5568 (SCYX-7158) is licensed to Drugs for Neglected Diseases initiative (DNDi) for the potential treatment of human African trypanosomiasis (sleeping sickness).